Table 1

Demographic and clinical features of patients with MOGADs

Total n=95Paediatrics n=51Adults n=44P value
Current age, years, median (range)16 (3–68)10 (3–18)32 (17–68)
Age of onset, years, median (range)13 (2–67)8 (2–14)30 (15–67)
Follow-up time, months, median (range)12(4–36)12(4–36)12(4–30)
Inducement, n (%)
 Previous infection22 (23)18 (35)4 (9)0.031
 Vaccine3 (3)2 (4)1 (2)>0.999
 Others3 (3)1 (2)2 (5)0.595
Phenotype at onset, n (%)*
 ON58 (61)25 (49)33 (75)0.012
 Myelitis11 (12)4 (8)7 (16)0.336
 Encephalopathy30 (32)26 (51)4 (9)<0.0001
 Brainstem syndrome6 (6)4 (8)2 (5)0.683
 Others4 (4)3 (6)1 (2)0.621
Initial EDSS, median (range)3 (1–8)3 (1–8)2 (1–5)0.024
Time to relapse, m median (range)†8 (1–81)10 (1–51)8 (1–81)0.480
Relapse type, n (%)*†
 ON56 (54)19 (40)37 (66)0.011
 Myelitis17 (17)4 (9)13 (23)0.062
 Encephalopathy31 (30)23 (49)8 (14)<0.001
 Brainstem syndrome9 (9)4 (9)5 (9)>0.999
 Others1 (1)01 (2)>0.999
Acute phase treatment, n (%)
 Intravenous MTP85/95 (90)47/51 (92)38/44 (86)0.506
 intravenous IG13/95 (14)12/51 (24)1/44 (2)0.025
 PLEX or IAD2/95 (2)1/51 (2)1/44 (2)>0.999
 None or others7/95 (7)3/51 (6)4/44 (9)0.701
Chronic therapies, n (%)
 Steroids67/95 (71)34/51 (67)33/44 (75)0.499
Immunosuppressive therapies18/95 (19)7/51 (14)11/44 (25)0.195
Immunomodulatory therapies7/95 (7)5/51 (10)2/44 (5)0.448
  • Values in bold indicate that there are differences between adults and paediatric individuals (p<0.05).

  • *Patients may exhibit multiple phenotypes simultaneously.

  • †Forty-six patients relapsed for a total of 103 relapses; 23 paediatric-onset patients with 47 relapses and 23 adult-onset patients with 56 relapses.

  • EDSS, Expanded Disability Status Scale; IAD, immunoadsorption; MOGADs, myelin oligodendrocyte glycoprotein-associated disorders; MTP, methylprednisolone; ON, optic neuritis; PLEX, plasma exchange.